Market Insight | ABBISKO-B rises by over 3% again, the research results of Pembrolizumab will demonstrate policy support for segmented production of domestic bioproducts
ABBISKO-B rose by over 3%, reaching a 3.63% increase as of the time of publication, closing at HKD 4 with a turnover of HKD 10.2586 million. On the news front, ABBISKO Pharma announced that the company will present its independently developed novel oral, highly selective, highly active CSF-1R small molecule inhibitor pimitinib for the treatment of tenosynovial giant cell tumor (TGCT) in a model-guided dose selection study at the 2024 American Conference on Pharmacometrics (ACoP). The ACoP conference will be held in Phoenix, USA from November 10th to 13th, 2024. Of note, the National Medical Products Administration recently reviewed and approved the "Pilot Program for Segmented Production of Biological Products." This pilot program is based on the current status and regulatory practices of China's biopharmaceutical industry, actively responding to the needs of industry development, and exploring the segmented production of some innovative and clinically urgent biological products through commissioned production. This will help further stimulate the innovation vitality of enterprises, promote specialization in drug research and development production, enhance the level of product quality and safety assurance, strengthen the supply guarantee capability of innovative and clinically urgent biological products, and meet the medication needs of the general public
According to the Wise Finance APP, ABBISKO-B (02256) has risen by over 3% again, up 3.63% as of the time of publication, reaching HKD 4, with a turnover of HKD 10.2586 million.
On the news front, ABBISKO Pharma announced that the company will present its independently developed novel oral, highly selective, highly active CSF-1R small molecule inhibitor pimitinib for the treatment of tenosynovial giant cell tumor (TGCT) at the 2024 American Conference on Pharmacometrics (ACoP). The ACoP conference will be held in Phoenix, USA from November 10th to 13th, 2024.
Of note, the National Medical Products Administration recently reviewed and approved the "Biological Products Segmented Production Pilot Program." This pilot program is based on the current status and regulatory practices of China's biopharmaceutical industry, actively responding to the needs of industry development. It aims to explore the segmented production of some innovative and clinically urgent biological products through commissioned production. This will help further stimulate the innovation vitality of enterprises, promote specialization in drug research and development production, enhance the level of product quality and safety assurance, strengthen the supply guarantee capacity of innovative and clinically urgent biological products, and meet the medication needs of the general public
